Pfizer Inc.
Combination of a PARP Inhibitor and a PD-1 Axis Binding Antagonist
Last updated:
Abstract:
This invention relates to a method of treating cancer by administering a PARP inhibitor in combination with a PD-1 axis binding antagonist to a patient in need thereof.
Status:
Application
Type:
Utility
Filling date:
10 Oct 2018
Issue date:
13 Aug 2020